{
  "docId": "019de073-187a-71e9-a3c0-2f4159454068",
  "docSlug": "48ce63a07f3c546c39a71c96ea43409e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 40,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Includes a screenshot of a NEJM research summary and a list of key clinical/regulatory milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-187a-71e9-a3c0-2f4159454068/21",
  "deckHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068",
  "deckJsonHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068.json",
  "deckAnchorHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.85,
        "y": 0.8
      },
      "kind": "image",
      "text": "Sanofi logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e06ec0f6-3aee-40c9-9a16-053e476106c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.25,
        "x": 0.12,
        "y": 0.27
      },
      "kind": "image",
      "text": "NEJM Research Summary",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5833ca4e-f715-47e2-966b-a4230140c42c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.3
      },
      "kind": "list",
      "text": "Designed and developed to protect all infants through their first RSV season with a single dose. 79.5% effective against medically attended LRTI. 77.3% effective against RSV LRTI hospitalisations. EMA and US FDA regulatory updates.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91c95a5a-cb5e-4193-9981-24eaf517e1cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.95,
        "x": 0.03,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "1. Simões, E, et al. ESPID. May 2022; 2. Hammitt LL, MD et al. NEJM. 2022;386(9):837-846; LRTI = lower respiratory tract infections; RSV = respiratory syncytial virus. EMA = European Medical Authority; US FDA = United States Food and Drug Administration.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "670f46cb-a78b-4d4a-aa32-4a41d8d38728",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Nirsevimab shown to be 77.3% effective against hospitalisations",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d6a45d6-c0eb-4ed2-b443-7f290fe332ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "BioPharmaceuticals: Q2 2022 R&D",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b19c8339-63b4-40ee-8f78-def907ef61b2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a659029d-0f0d-4206-a067-550ee85965cd",
      "evidence": "list/bullet: Designed and developed to protect all infants through their first RSV season with a single dose. 79.5% effective against medically attended LRTI. 77.3% effective against RSV LRTI hospitalisations. EMA and US",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}